Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Leases (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Current Leases for 4 consecutive years, with $136000.0 as the latest value for Q4 2025.

  • Quarterly Current Leases fell 44.72% to $136000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $136000.0 through Dec 2025, down 44.72% year-over-year, with the annual reading at $136000.0 for FY2025, 44.72% down from the prior year.
  • Current Leases hit $136000.0 in Q4 2025 for NewAmsterdam Pharma, down from $181000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $252000.0 in Q1 2025 to a low of $43000.0 in Q1 2024.
  • Historically, Current Leases has averaged $168025.5 across 4 years, with a median of $203000.0 in 2025.
  • Biggest YoY gain for Current Leases was 486.05% in 2025; the steepest drop was 44.72% in 2025.
  • Year by year, Current Leases stood at $63255.3 in 2022, then dropped by 5.15% to $60000.0 in 2023, then soared by 310.0% to $246000.0 in 2024, then plummeted by 44.72% to $136000.0 in 2025.
  • Business Quant data shows Current Leases for NAMS at $136000.0 in Q4 2025, $181000.0 in Q3 2025, and $225000.0 in Q2 2025.